382. SGLT Inhibitors: The Data Supporting SGL...

This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. The following question refers to Sections 4.3.2 and 4.4 of the 2025 ACS Guidelines. The ques ...  عرض المزيد

This episode is part of our comprehensive Decipher the Guidelines Series covering the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. The following question refers to Section 3.2 of the 2025 ACS Guidelines. The question is ask ...  عرض المزيد

Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects. Relevant disclosures can be found with the episode show notes on Medscape ( https://www.medscape.com/vie ...  عرض المزيد

Join experts Drs Matthew Sparks and James Matthew Luther as they discuss how and why they're using mineralocorticoid receptor antagonists to treat patients with diabetic kidney disease in their practice. Relevant disclosures can be found with the episode show notes on Medscape (h ...  عرض المزيد

SGLT2 inhibitors, publishing choices, second and third order effects of interventions, decision support, and patient selection for preventive procedures are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare profe ...

Have you noticed that your patients are being prescribed SGLT-2 inhibitors, even if they don't have diabetes? If your patient asked, would you be able to explain why they are taking an SGLT-2 inhibitor?Listen in to learn about how this new and fascinating class of medication that ...  عرض المزيد